Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT

the real life experience of Rete Ematologica Pugliese (REP)

Vincenzo Pavone, Anna Mele, Daniela Carlino, Giorgina Specchia, Francesco Gaudio, Tommasina Perrone, Patrizio Mazza, Giulia Palazzo, Attilio Guarini, Giacomo Loseto, Prete Eleonora, Nicola Cascavilla, Potito Scalzulli, Angela Melpignano, Giovanni Quintana, Nicola Di Renzo, Giuseppe Tarantini, Silvana Capalbo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Brentuximab vedotin (BV) shows a high overall response rate (ORR) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) after autologous transplant (ASCT). The aim of this multicenter study, conducted in nine Hematology Departments of Rete Ematologica Pugliese, was to retrospectively evaluate the efficacy and safety of BV as salvage therapy and as bridge regimen to ASCT or allogeneic transplant (alloSCT) in R/R HL patients. Seventy patients received BV. Forty-five patients (64%) were treated with BV as bridge to transplant:16 (23%) patients as bridge to ASCT and 29 (41%) as bridge to alloSCT. Twenty-five patients (36%), not eligible for transplant, received BV as salvage treatment. The ORR was 59% (CR 26%). The ORR in transplant naïve patients was 75% (CR 31%). In patients treated with BV as bridge to alloSCT, the ORR was 62% (CR 24%). In a multivariate analysis, the ORR was lower in refractory patients (p < 0.005). The 2y-OS was 70%. The median PFS was 17 months. Ten of the 16 (63%) naïve-transplant patients received ASCT, with 50% in CR before ASCT. In the 29 patients treated with BV as bridge to alloSCT, 28 (97%) proceeded to alloSCT with 25% in CR prior to alloSCT. The most common adverse events were peripheral neuropathy (50%), neutropenia (29%) and anemia (12%). These data suggest that BV is well tolerated and very effective in R/R HL, producing a substantial level of CR. BV may also be a key therapeutic agent to achieve good disease control before transplant, improving post- transplant outcomes, also in refractory and heavily pretreated patients, without significant overlapping toxicities with prior therapies.

Original languageEnglish
Pages (from-to)1817-1824
Number of pages8
JournalAnnals of Hematology
Volume97
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Salvage Therapy
Life Change Events
Hodgkin Disease
Transplants
cAC10-vcMMAE
Autografts
Peripheral Nervous System Diseases
Hematology
Neutropenia
Multicenter Studies
Anemia
Multivariate Analysis

Keywords

  • Autologous and allogeneic stem cell transplant
  • Brentuximab vedotin salvage treatment
  • Relapsed/refractory Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT : the real life experience of Rete Ematologica Pugliese (REP). / Pavone, Vincenzo; Mele, Anna; Carlino, Daniela; Specchia, Giorgina; Gaudio, Francesco; Perrone, Tommasina; Mazza, Patrizio; Palazzo, Giulia; Guarini, Attilio; Loseto, Giacomo; Eleonora, Prete; Cascavilla, Nicola; Scalzulli, Potito; Melpignano, Angela; Quintana, Giovanni; Di Renzo, Nicola; Tarantini, Giuseppe; Capalbo, Silvana.

In: Annals of Hematology, Vol. 97, No. 10, 01.10.2018, p. 1817-1824.

Research output: Contribution to journalArticle

Pavone, V, Mele, A, Carlino, D, Specchia, G, Gaudio, F, Perrone, T, Mazza, P, Palazzo, G, Guarini, A, Loseto, G, Eleonora, P, Cascavilla, N, Scalzulli, P, Melpignano, A, Quintana, G, Di Renzo, N, Tarantini, G & Capalbo, S 2018, 'Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)', Annals of Hematology, vol. 97, no. 10, pp. 1817-1824. https://doi.org/10.1007/s00277-018-3379-5
Pavone, Vincenzo ; Mele, Anna ; Carlino, Daniela ; Specchia, Giorgina ; Gaudio, Francesco ; Perrone, Tommasina ; Mazza, Patrizio ; Palazzo, Giulia ; Guarini, Attilio ; Loseto, Giacomo ; Eleonora, Prete ; Cascavilla, Nicola ; Scalzulli, Potito ; Melpignano, Angela ; Quintana, Giovanni ; Di Renzo, Nicola ; Tarantini, Giuseppe ; Capalbo, Silvana. / Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT : the real life experience of Rete Ematologica Pugliese (REP). In: Annals of Hematology. 2018 ; Vol. 97, No. 10. pp. 1817-1824.
@article{d7739029a32043a685d3e34455fcf7e3,
title = "Brentuximab vedotin as salvage treatment in Hodgkin lymphoma na{\"i}ve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)",
abstract = "Brentuximab vedotin (BV) shows a high overall response rate (ORR) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) after autologous transplant (ASCT). The aim of this multicenter study, conducted in nine Hematology Departments of Rete Ematologica Pugliese, was to retrospectively evaluate the efficacy and safety of BV as salvage therapy and as bridge regimen to ASCT or allogeneic transplant (alloSCT) in R/R HL patients. Seventy patients received BV. Forty-five patients (64{\%}) were treated with BV as bridge to transplant:16 (23{\%}) patients as bridge to ASCT and 29 (41{\%}) as bridge to alloSCT. Twenty-five patients (36{\%}), not eligible for transplant, received BV as salvage treatment. The ORR was 59{\%} (CR 26{\%}). The ORR in transplant na{\"i}ve patients was 75{\%} (CR 31{\%}). In patients treated with BV as bridge to alloSCT, the ORR was 62{\%} (CR 24{\%}). In a multivariate analysis, the ORR was lower in refractory patients (p < 0.005). The 2y-OS was 70{\%}. The median PFS was 17 months. Ten of the 16 (63{\%}) na{\"i}ve-transplant patients received ASCT, with 50{\%} in CR before ASCT. In the 29 patients treated with BV as bridge to alloSCT, 28 (97{\%}) proceeded to alloSCT with 25{\%} in CR prior to alloSCT. The most common adverse events were peripheral neuropathy (50{\%}), neutropenia (29{\%}) and anemia (12{\%}). These data suggest that BV is well tolerated and very effective in R/R HL, producing a substantial level of CR. BV may also be a key therapeutic agent to achieve good disease control before transplant, improving post- transplant outcomes, also in refractory and heavily pretreated patients, without significant overlapping toxicities with prior therapies.",
keywords = "Autologous and allogeneic stem cell transplant, Brentuximab vedotin salvage treatment, Relapsed/refractory Hodgkin lymphoma",
author = "Vincenzo Pavone and Anna Mele and Daniela Carlino and Giorgina Specchia and Francesco Gaudio and Tommasina Perrone and Patrizio Mazza and Giulia Palazzo and Attilio Guarini and Giacomo Loseto and Prete Eleonora and Nicola Cascavilla and Potito Scalzulli and Angela Melpignano and Giovanni Quintana and {Di Renzo}, Nicola and Giuseppe Tarantini and Silvana Capalbo",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s00277-018-3379-5",
language = "English",
volume = "97",
pages = "1817--1824",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT

T2 - the real life experience of Rete Ematologica Pugliese (REP)

AU - Pavone, Vincenzo

AU - Mele, Anna

AU - Carlino, Daniela

AU - Specchia, Giorgina

AU - Gaudio, Francesco

AU - Perrone, Tommasina

AU - Mazza, Patrizio

AU - Palazzo, Giulia

AU - Guarini, Attilio

AU - Loseto, Giacomo

AU - Eleonora, Prete

AU - Cascavilla, Nicola

AU - Scalzulli, Potito

AU - Melpignano, Angela

AU - Quintana, Giovanni

AU - Di Renzo, Nicola

AU - Tarantini, Giuseppe

AU - Capalbo, Silvana

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Brentuximab vedotin (BV) shows a high overall response rate (ORR) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) after autologous transplant (ASCT). The aim of this multicenter study, conducted in nine Hematology Departments of Rete Ematologica Pugliese, was to retrospectively evaluate the efficacy and safety of BV as salvage therapy and as bridge regimen to ASCT or allogeneic transplant (alloSCT) in R/R HL patients. Seventy patients received BV. Forty-five patients (64%) were treated with BV as bridge to transplant:16 (23%) patients as bridge to ASCT and 29 (41%) as bridge to alloSCT. Twenty-five patients (36%), not eligible for transplant, received BV as salvage treatment. The ORR was 59% (CR 26%). The ORR in transplant naïve patients was 75% (CR 31%). In patients treated with BV as bridge to alloSCT, the ORR was 62% (CR 24%). In a multivariate analysis, the ORR was lower in refractory patients (p < 0.005). The 2y-OS was 70%. The median PFS was 17 months. Ten of the 16 (63%) naïve-transplant patients received ASCT, with 50% in CR before ASCT. In the 29 patients treated with BV as bridge to alloSCT, 28 (97%) proceeded to alloSCT with 25% in CR prior to alloSCT. The most common adverse events were peripheral neuropathy (50%), neutropenia (29%) and anemia (12%). These data suggest that BV is well tolerated and very effective in R/R HL, producing a substantial level of CR. BV may also be a key therapeutic agent to achieve good disease control before transplant, improving post- transplant outcomes, also in refractory and heavily pretreated patients, without significant overlapping toxicities with prior therapies.

AB - Brentuximab vedotin (BV) shows a high overall response rate (ORR) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) after autologous transplant (ASCT). The aim of this multicenter study, conducted in nine Hematology Departments of Rete Ematologica Pugliese, was to retrospectively evaluate the efficacy and safety of BV as salvage therapy and as bridge regimen to ASCT or allogeneic transplant (alloSCT) in R/R HL patients. Seventy patients received BV. Forty-five patients (64%) were treated with BV as bridge to transplant:16 (23%) patients as bridge to ASCT and 29 (41%) as bridge to alloSCT. Twenty-five patients (36%), not eligible for transplant, received BV as salvage treatment. The ORR was 59% (CR 26%). The ORR in transplant naïve patients was 75% (CR 31%). In patients treated with BV as bridge to alloSCT, the ORR was 62% (CR 24%). In a multivariate analysis, the ORR was lower in refractory patients (p < 0.005). The 2y-OS was 70%. The median PFS was 17 months. Ten of the 16 (63%) naïve-transplant patients received ASCT, with 50% in CR before ASCT. In the 29 patients treated with BV as bridge to alloSCT, 28 (97%) proceeded to alloSCT with 25% in CR prior to alloSCT. The most common adverse events were peripheral neuropathy (50%), neutropenia (29%) and anemia (12%). These data suggest that BV is well tolerated and very effective in R/R HL, producing a substantial level of CR. BV may also be a key therapeutic agent to achieve good disease control before transplant, improving post- transplant outcomes, also in refractory and heavily pretreated patients, without significant overlapping toxicities with prior therapies.

KW - Autologous and allogeneic stem cell transplant

KW - Brentuximab vedotin salvage treatment

KW - Relapsed/refractory Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85050906638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050906638&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3379-5

DO - 10.1007/s00277-018-3379-5

M3 - Article

VL - 97

SP - 1817

EP - 1824

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 10

ER -